Efficacy of iclaprim against wild-type and thymidine kinase-deficient methicillin-resistant Staphylococcus aureus isolates in an in vitro fibrin clot model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 9, 2009, Pages 3635-3641

  Entenza, José M ^a   Haldimann, Andreas ^b   Giddey, Marlyse ^a   Lociuro, Sergio ^b   Hawser, Stephen ^b,c   Moreillon, Philippe ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Arpida Ltd   (Switzerland)

^c International Health Management Associates Europe Sàrl   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; F OO68; ICLAPRIM; L 011081; THYMIDINE KINASE; UNCLASSIFIED DRUG; VANCOMYCIN; Z 30708;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG EFFICACY; FIBRIN CLOT; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUTATION; PYRIMIDINES; RATS; THYMIDINE KINASE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN;

EID: 70349083747     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00325-09     Document Type: Article

References (37)

1. Adra, M., and K. R. Lawrence. 2004. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann. Pharmacother. 38:338-341.
2. Appelbaum, P. C. 2006. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 12(Suppl. 1):16-23.
3. Besier, S., J. Zander, E. Siegel, S. H. Saum, K. P. Hunfeld, A. Ehrhart, V. Brade, and T. A. Wichelhaus. 2008. Thymidine-dependent Staphylococcus aureus small-colony variants: human pathogens that are relevant not only in cases of cystic fibrosis lung disease. J. Clin. Microbiol. 46:3829-3832.
4. Brandt, R., S. Warrington, A. McBurney, and K. Islam. 2007. Tolerability and pharmacokinetics of single and repeat ascending doses of iclaprim in healthy adults, abstr. A-804. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
5. Chambers, H. F. 2001. The changing epidemiology of Staphylococcus aureus? Emerg. Infect. Dis. 7:178-182.
6. Chang, S., D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover, F. P. Downes, S. Shah, J. T. Rudrik, G. R. Pupp, W. J. Brown, D. Cardo, and S. K. Fridkin. 2003. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N. Engl. J. Med. 348:1342-1347.
7. CLSI. 2006. Methods for antimicrobial susceptibility test for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. CLSI, Wayne, PA.
8. de Górgolas, M., P. Aviles, C. Verdejo, and M. L. Fernandez Guerrero. 1995. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob. Agents Chemother. 39:953-957.
9. Entenza, J. M., H. Drugeon, M. P. Glauser, and P. Moreillon. 1995. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob. Agents Chemother. 39:1419-1424.
10. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1999. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis. Antimicrob. Agents Chemother. 43:77-84.
11. Finberg, R. W., R. C. Moellering, F. P. Tally, W. A. Craig, G. A. Pankey, E. P. Dellinger, M. A. West, M. Joshi, P. K. Linden, K. V. Rolston, J. C. Rotschafer, and M. J. Rybak. 2004. The importance of bactericidal drugs: future directions in infectious disease. Clin. Infect. Dis. 39:1314-1320.
12. Grayson, M. L., C. Thauvin-Eliopoulos, G. M. Eliopoulos, J. D. Yao, D. V. DeAngelis, L. Walton, J. L. Woolley, and R. C. Moellering, Jr. 1990. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis. Antimicrob. Agents Chemother. 34:1792-1794.
13. Haldimann, A., S. Fels, S. Rigo, K. Islam, and S. Lociuro. 2006. Effect of thymidine on the activity of diaminopyrimidine antibacterial agents. Part I: generation and characterization of thymidine kinase-deficient S. aureus mutants, abstr. CI-940. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
14. Hamilton-Miller, J. M. 1988. Reversal of activity of trimethoprim against gram-positive cocci by thymidine, thymine and 'folates.' J. Antimicrob. Chemother. 22:35-39.
15. Hawser, S., S. Lociuro, and K. Islam. 2006. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem. Pharmacol. 71:941-948.
16. Hershberger, E., E. A. Coyle, G. W. Kaatz, M. J. Zervos, and M. J. Rybak. 2000. Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 44:1921-1924.
17. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
18. Jones, C., D. L. Stevens, and O. Ojo. 1987. Effect of minimal amounts of thymidine on activity of trimethoprim-sulfamethoxazole against Staphylococcus epidermidis. Antimicrob. Agents Chemother. 31:144-147.
19. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H. Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E. Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
20. Laue, H., T. Valensise, A. Seguin, S. Hawser, S. Lociuro, and K. Islam. 2007. Effect of human plasma on the antimicrobial activity of iclaprim in vitro. J. Antimicrob. Chemother. 60:1388-1390.
21. Laue, H., L. Weiss, A. Bernardi, S. Hawser, S. Lociuro, and K. Islam. 2007. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J. Antimicrob. Chemother. 60:1391-1394.
22. Lee, B. L., M. Sachdeva, and H. F. Chambers. 1991. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 35:2505-2508.
23. Lowy, F. D. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Investig. 111:1265-1273.
24. Markowitz, N., E. L. Quinn, and L. D. Saravolatz. 1992. Trimethoprimsulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann. Intern. Med. 117:390-398.
25. McDonald, L. C. 2006. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin. Infect. Dis. 42(Suppl. 2):S65-S71.
26. McGrath, B. J., S. L. Kang, G. W. Kaatz, and M. J. Rybak. 1994. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob. Agents Chemother. 38:2034-2040.
27. Nottebrock, H., and R. Then. 1977. Thymidine concentrations in serum and urine of different animal species and man. Biochem. Pharmacol. 26:2175-2179.
28. Oefner, C., M. Bandera, A. Haldimann, H. Laue, H. Schulz, S. Mukhija, S. Parisi, L. Weiss, S. Lociuro, and G. E. Dale. 2009. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. J. Antimicrob. Chemother. 63:687-698.
29. Rybak, M. J. 2006. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42(Suppl. 1):S35-S39.
30. Salgado, C. D., and B. M. Farr. 2004. Community-acquired methicillin-resistant Staphylococcus aureus. JAMA 291:1960-1961.
31. Schneider, P., S. Hawser, and K. Islam. 2003. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg. Med. Chem. Lett. 13:4217-4221.
32. Stein, A., J. F. Bataille, M. Drancourt, G. Curvale, J. N. Argenson, P. Groulier, and D. Raoult. 1998. Ambulatory treatment of multidrug-resistant Staphylococcus-infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). Antimicrob. Agents Chemother. 42:3086-3091.
33. Stevens, R. C., S. C. Laizure, P. L. Sanders, and D. S. Stein. 1993. Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Antimicrob. Agents Chemother. 37:448-452.
34. Tokunaga, T., K. Oka, A. Takemoto, Y. Ohtsubo, N. Gotoh, and T. Nishino. 1997. Efficacy of trimethoprim in murine experimental infection with a thymidine kinase-deficient mutant of Escherichia coli. Antimicrob. Agents Chemother. 41:1042-1045. (Pubitemid 27194182)
35. Varoquaux, O., D. Lajoie, C. Gobert, P. Cordonnier, C. Ducreuzet, M. Pays, and C. Advenier. 1985. Pharmacokinetics of the trimethoprim- sulphamethoxazole combination in the elderly. Br. J. Clin. Pharmacol. 20:575-581.
36. Vickers, A. A., N. J. Potter, C. W. Fishwick, I. Chopra, and A. J. O'Neill. 2009. Analysis of mutational resistance to trimethoprim in Staphylococcus aureus by genetic and structural modelling techniques. J. Antimicrob. Chemother. 63:1112-1117.
37. Vouillamoz, J., P. Moreillon, M. Giddey, and J. M. Entenza. 2006. Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J. Antimicrob. Chemother. 58:1208-1214.